The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

IN BRIEF: Verona Pharma To Delist From AIM But Remain On Nasdaq

Mon, 21st Sep 2020 14:12

Verona Pharma PLC - clinical-stage biopharmaceutical company - To cancel trading of shares on AIM market. Last day of trading October 29 and delisting will be effective from October 30. To retain the listing of its American Depositary Shares on the Nasdaq Global Market. As of Thursday last week, 93% of the company's shares are held in ADS form and tradeable on Nasdaq, with 98% of trading in the past six months taking place on Nasdaq.

Current stock price: 61.41 pence

Year-to-date change: down 0.9%

By Tapan Panchal; tapanpanchal@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News
29 Oct 2020 19:09

IN BRIEF: Verona Pharma Says Third Quarter Loss Widens

IN BRIEF: Verona Pharma Says Third Quarter Loss Widens

22 Oct 2020 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

14 Sep 2020 13:13

IN BRIEF: Cambridge Cognition Hires Diurnal CFO Bungay As Non-Exec

IN BRIEF: Cambridge Cognition Hires Diurnal CFO Bungay As Non-Exec

24 Aug 2020 11:09

Verona Pharma Says Study Shows Ensifentrine Improves Lung Function

Verona Pharma Says Study Shows Ensifentrine Improves Lung Function

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.